Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From IRIDEX Corp.
Advanz has acquired exclusive rights to register and commercialize a Phase III candidate from Dimerix in multiple territories, alongside agreements with Kyowa Kirin, Bayer and GP Pharm.
In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.
Veteran pharma leader Martin Mackay, CEO of Rallybio, recently spoke with In Vivo about building a new company on the cusp of retirement, what drives him, how he leads and what he is excited about in the company’s pipeline.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.